Tonix Pharmaceuticals announced the submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for TNX-102 SL 5.6 mg, a non-opioid, centrally-acting analgesic that showed statistically significant reduction in the chronic, widespread pain associated with fibromyalgia in two Phase 3 studies and was generally well tolerated. TNX-102 SL was granted Fast Track designation for fibromyalgia by the FDA in July of 2024. Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals announces AI collaboration with X-Chem
- Tonix Pharma Enhances Drug Development with AI Partnership
- 3 Penny Stocks to Watch Now, 10/01/24
- Tonix Pharmaceuticals (TNXP) Has a Promising Pipeline but Faces Financial Challenges
- Tonix Pharmaceuticals participates in Endpoints panel at RECOVER workshop